
Microbot Medical Inc (AKA: StemCells Inc~Cellular Transplants~Cytotherapeutics Inc~CytoTherapeutics Inc) Profile last edited on: 6/4/2024
CAGE: 507G3
UEI: EJ27HMVA7VM9
Business Identifier: Pre-clinical medical device company specializing in the research, design, and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
288 Grove Street Suite 388
Braintree, MA 02184
Braintree, MA 02184
(781) 875-3605 |
info@microbotmedical.com |
www.microbotmedical.com |
Location: Multiple
Congr. District: 08
County: Norfolk
Congr. District: 08
County: Norfolk
Public Profile
Having been renamed several times, until 2016 the firm was dba as StemCells (NASDAQ:STEM). In Novermber 2016 - in some trouble, the firm did a reverse merger with privately held, Israeli firm MicroBot Medical and now trades under that name (NASDAQ:MBOT). Where the orginal StemCells had been organized around cell-based therapeutics and related technologies for stem cell-based research and drug discovery and development: stem cell therapies and encapsulated cell therapies. With a total personnel restructure, the new entity dba Microbot Medical and is a medical device company specializing in the design and development of transformational micro-robotic medical technologies, primarily focused on leveraging its micro-robotic technologies with the goal of allowing more physicians to treat more patients while improving surgical outcomes for patients. With its HQ and faciliites in Hingham, MA the firm's first two product candidates: the Self Cleaning Shunt, or SCS, for the treatment of hydrocephalus and Normal Pressure Hydrocephalus, or NPH; and TipCAT, a self-propelling, semi-disposable endoscope that is being developed initially for use in colonoscopy procedures.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
20-24Revenue Range
2M-2.5MVC funded?
YesPublic/Private
Publicly TradedStock Info
NASDAQ : MBOTIP Holdings
25-49Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2010 | 1 | NIH | $403,885 | |
Project Title: Towards The Creation Of Hcv-Resistant Liver Cells For Transplantation | ||||
2005 | 2 | NIH | $464,276 | |
Project Title: CNS Stem Cells for Alzheimer's Disease Therapy | ||||
2003 | 1 | NIH | $342,493 | |
Project Title: Testing of human CNS-SC in a spinal cord injury model | ||||
2002 | 2 | NIH | $600,000 | |
Project Title: Liver Stem Cells And Humanized Mice: A New Model For HCV | ||||
2000 | 1 | NIH | $198,614 | |
Project Title: Testing Of Normal Human Cns-Nsc In A Parkinson's Model |
Key People / Management
Harel Gadot -- CEO President and Chairman
Yoseph Bornstein -- Co-Founder & Independent Director
Alexandra Capela
George A Carlson
Lisa Christenson
Juan Diaz-Cartelle -- Chief Medical Officer
Orion D Hegre
William F Hickey
Stephen Huhn -- Vice President, Clinical Research and Chief Medical Officer
Jakop Jacobs
Eric Lagasse
Michael J Lysaght
Joel Naor -- Vice President, Clinical Development, Ophthalmology
Simon Sharon -- CTO & GM of Microbot Israel
Ann Tsukamoto -- Executive Vice President, Scientific and Strategic Alliances
Nobuko Uchida -- Vice President, Stem Cell Biology
Rachel Vaknin -- Chief Financial Officer
Yoseph Bornstein -- Co-Founder & Independent Director
Alexandra Capela
George A Carlson
Lisa Christenson
Juan Diaz-Cartelle -- Chief Medical Officer
Orion D Hegre
William F Hickey
Stephen Huhn -- Vice President, Clinical Research and Chief Medical Officer
Jakop Jacobs
Eric Lagasse
Michael J Lysaght
Joel Naor -- Vice President, Clinical Development, Ophthalmology
Simon Sharon -- CTO & GM of Microbot Israel
Ann Tsukamoto -- Executive Vice President, Scientific and Strategic Alliances
Nobuko Uchida -- Vice President, Stem Cell Biology
Rachel Vaknin -- Chief Financial Officer